Compare ALTI & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | ASMB |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | 490 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 442.9M |
| IPO Year | 2021 | 2010 |
| Metric | ALTI | ASMB |
|---|---|---|
| Price | $3.86 | $30.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | ★ 147.7K | 125.5K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.11 | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $254,956,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $10.71 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.96 | $13.13 |
| 52 Week High | $5.45 | $39.71 |
| Indicator | ALTI | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 57.87 |
| Support Level | $3.73 | $26.50 |
| Resistance Level | $3.96 | $30.58 |
| Average True Range (ATR) | 0.21 | 1.55 |
| MACD | 0.03 | 0.36 |
| Stochastic Oscillator | 82.85 | 71.79 |
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.